In another study, it was found that compared with wild-type EGFR, exon 19 deletions were associated with significantly worse response rates and progression-free survival (PFS) after anti-PD-1/PD-L1 therapy in NSCLC patients, and the outcomes for patients carrying L858R EGFR and wild-type EGFR were similar,[27] which may be explained by the correlation of PD-L1 expression and different EGFR mutation types in our study. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.